Is Design Therapeutics, Inc. (DSGN) a Buy, Sell, or Hold?
NASDAQ : DSGN
Design Therapeutics, Inc. — News
$12.18 USD
-$0.44 (-3.49%)
- Volume
- 624.96K
- Average Volume
- 944.59K
- Market Capitalization
- $760.73M
- P/E Ratio
- -10.15
- Dividend Yield
- 0.00%
- Price Target
- $20.50
- Year High
- $17.25
- Year Low
- $3.85
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $22.28
| Source | Headline |
|---|---|
|
Design Therapeutics Announces Initiation of Patient Dosing in Phase 1 Multiple Ascending Dose Trial of DT-818 for Myotonic Dystrophy Type-1
GeneTAC ® small molecule designed to selectively reduce transcription of the mutant DMPK allele and address the underlying cause of DM1 CARLSBAD, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced the initiation of patient dosing in its Phase 1 multiple-ascending dose (MAD) clinical trial evaluating DT-818 in adults with myotonic dystrophy type-1 (DM1). globenewswire.com - 2026-06-30 08:00:00 |
|
Design Therapeutics: FA Early Data And FDA Discussions Are Promising Catalysts
Design Therapeutics has its proprietary GeneTAC platform. This gives them a small-molecule way to target repeat-expansion diseases. Their main value driver and drug candidate is DT-216P2 for FA. DSGN's trial on DT-216P2 is RESTORE-FA. This trial produced data that I believe makes DT-216P2 much more credible. seekingalpha.com - 2026-06-24 18:07:55 |
|
Design Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference
CARLSBAD, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat during the 2026 Jefferies Global Healthcare Conference on Thursday, June 4, 2026, at 1:25 p.m. globenewswire.com - 2026-05-28 08:00:00 |
|
Design Therapeutics Stock Wobbles After Rare Genetic Disease Data
Design Therapeutics Inc. (NASDAQ:DSGN) stock surged during the premarket session on Monday. benzinga.com - 2026-05-18 14:26:20 |
|
Design Therapeutics, Inc. (DSGN) Discusses Data from RESTORE-FA Trial of DT-216P2 for Friedreich Ataxia Transcript
Design Therapeutics, Inc. (DSGN) Discusses Data from RESTORE-FA Trial of DT-216P2 for Friedreich Ataxia Transcript seekingalpha.com - 2026-05-18 11:00:50 |
|
Design Therapeutics Announces Four-Week IV Data from the RESTORE-FA Trial of DT-216P2 Demonstrating Clinical Improvements and Comprehensive Biomarker Activity in Friedreich Ataxia
DT-216P2 demonstrated dose-dependent improvement in multiple clinical measures and increases in endogenous frataxin mRNA and protein after four weeks of intravenous dosing globenewswire.com - 2026-05-18 07:00:00 |
|
Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich's Ataxia on Monday, May 18, 2026
CARLSBAD, Calif., May 17, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, will announce data from the ongoing Phase 1/2 RESTORE-FA trial evaluating DT-216P2 in patients with Friedreich's ataxia (FA) on Monday, May 18, 2026. Management will host a conference call and webcast at 8:00 a.m. ET. globenewswire.com - 2026-05-17 16:00:00 |
|
Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreich’s Ataxia on Monday, May 18, 2026
CARLSBAD, Calif. , May 17, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, will announce data from the ongoing Phase 1/2 RESTORE-FA trial evaluating DT-216P2 in patients with Friedreich's ataxia (FA) on Monday, May 18, 2026. globenewswire.com - 2026-05-17 16:00:00 |
|
Design Therapeutics, Inc. (DSGN) Is Up 6.92% in One Week: What You Should Know
Does Design Therapeutics, Inc. (DSGN) have what it takes to be a top stock pick for momentum investors? Let's find out. zacks.com - 2026-05-11 13:01:17 |
